Silver Book Fact

A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.

Ravina, Bernard M., Susan C. Fagan, Robert G. Hart, Collin A. Hovinga, Diane D. Murphy, Ted M. Dawson, and John R. Marler. Neuroprotective Agents for Clinical Trials in Parkinson’s Disease: A systematic assessment. Neurology. 2003; 60(8): 1234-40. http://www.neurology.org/cgi/pmidlookup?view=long&pmid=12707423

Reference

Title
Neuroprotective Agents for Clinical Trials in Parkinson’s Disease: A systematic assessment
Publication
Neurology
Publication Date
2003
Authors
Ravina, Bernard M., Susan C. Fagan, Robert G. Hart, Collin A. Hovinga, Diane D. Murphy, Ted M. Dawson, and John R. Marler
Volume & Issue
Volume 60, Issue 8
Pages
1234-40
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s…  
  • Combining gains in health-related knowledge of Alzheimer’s disease and its application for both genders, reductions in mortality between 1970 and 2000 yielded additional life-years with an end of century value…  
  • Willena is 75 and was diagnosed with Alzheimer’s disease five years ago Her daughter and primary caregiver, Wanda
    “Willena is 75 and was diagnosed with Alzheimer’s disease five years ago. Her daughter and primary caregiver, Wanda Richardson, believes that her mother went undiagnosed for at least 15 years…  
  • In a study of different treatments for Parkinson’s disease, results showed that the disease can be managed for up to 5 years with a reduces risk of dyskinesia.  
  • In one study, despite a 4-fold increase in prescription drug spending, overall health spending for Alzheimer’s patients undergoing drug therapy went down by 1/3.